Optinose_logo_RGB.png
Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference
02 déc. 2024 15h53 HE | Optinose, Inc.
YARDLEY, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose_logo_RGB.png
Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights
12 nov. 2024 07h00 HE | Optinose, Inc.
Company reports Q3 2024 XHANCE net revenue of $20.4 million, an increase of 3% compared to Q3 2023 Company reports positive inflection in new prescriptions of XHANCE starting in September Company...
Optinose_logo_RGB.png
Optinose Announces Reporting Date for Third Quarter 2024 Financial Results
05 nov. 2024 16h30 HE | Optinose, Inc.
YARDLEY, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose_logo_RGB.png
New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery
05 sept. 2024 09h00 HE | Optinose, Inc.
YARDLEY, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose_logo_RGB.png
Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference
26 août 2024 09h00 HE | Optinose, Inc.
YARDLEY, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose_logo_RGB.png
Optinose Reports Second Quarter 2024 Financial Results and Recent Operational Highlights
08 août 2024 07h00 HE | Optinose, Inc.
Company reports Q2 2024 XHANCE net revenue of $20.5 million, an increase of 5% compared to Q2 2023 XHANCE has been added to Express Scripts’ national formularies, among the largest commercial...
Optinose_logo_RGB.png
Optinose Announces Reporting Date for Second Quarter 2024 Financial Results
02 août 2024 08h30 HE | Optinose, Inc.
YARDLEY, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose_logo_RGB.png
Expanded Access to XHANCE with Addition to National Commercial Formularies
27 juin 2024 07h00 HE | Optinose, Inc.
YARDLEY, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose_logo_RGB.png
Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
17 mai 2024 12h00 HE | Optinose, Inc.
YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose_logo_RGB.png
Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights
14 mai 2024 07h00 HE | Optinose, Inc.
Company reports Q1 2024 XHANCE net revenue of $14.9 million, an increase of 26% compared to Q1 2023 Company expects full year 2024 XHANCE net revenues to be between $85.0 to $95.0 million ...